Prostate SABR practice varied despite broad adoption across Australia and New Zealand
Most surveyed oncologists offered prostate SABR, but patient selection, target volumes, focal boosts and access to supporting technology varied.
Tag
prostate
Hydrogel spacers reduced invasive treatment for radiation proctitis after prostate radiotherapy
Hydrogel spacer placement was associated with a 74% lower risk of gastrointestinal endoscopic hemostasis after prostate radiotherapy.
Daily adaptation improved target coverage and rectal sparing in postoperative prostate radiotherapy
Daily adaptation increased prostate-bed coverage from 92.1% to 98.5% and reduced high-dose rectal exposure during hypofractionated salvage radiotherapy.
Five-fraction prostate radiotherapy reduced estimated carbon emissions by 59%
Five-fraction prostate radiotherapy produced 58.6% lower estimated carbon emissions than a 26-fraction schedule, mainly by reducing patient travel.
Two-fraction HDR brachytherapy achieved durable control in favourable-risk prostate cancer
High-dose-rate brachytherapy using 13.5 Gy twice achieved 81.6% ten-year biochemical control with limited late genitourinary toxicity.
Robust IMPT modestly reduced organ-at-risk dose in five-fraction prostate proton therapy
SFUD and robust IMPT maintained target coverage under uncertainty, while IMPT modestly reduced rectal and bladder dose.
Prostate reirradiation strategies remain heterogeneous despite encouraging prospective outcomes
Prospective prostate reirradiation studies reported generally acceptable toxicity, but target volumes, dose schedules and organ constraints varied substantially.
SPPORT intensification did not worsen long-term quality of life
Short-term androgen deprivation impaired early sexual and hormonal quality of life, but treatment-arm differences were not clinically significant at five years.
Upright carbon ion plans matched supine dosimetry for prostate cancer
Upright carbon ion treatment plans achieved target coverage, organ sparing and simulated robustness comparable with conventional supine plans.
MRI-guided prostate SBRT reduced low-dose exposure to sexual-function structures
MRI-guided SBRT with 2-mm margins reduced low- and intermediate-dose exposure of neurovascular bundles and pudendal arteries versus CT-guided treatment.
DEGRO supports ultrahypofractionation for localized prostate cancer but flags higher late urinary toxicity
DEGRO supports ultrahypofractionation for low- to intermediate-risk prostate cancer, with comparable control but increased late genitourinary toxicity in selected patients.
Five-fraction prostate and pelvic nodal SBRT showed low late toxicity
After prostate and pelvic nodal SBRT, no grade ≥3 late GU or GI toxicity occurred among 101 patients with high-risk disease.
Pelvis-inclusive SBRT reduced acute gastrointestinal toxicity in high-risk prostate cancer
Once-weekly prostate-and-pelvis SBRT reduced acute gastrointestinal toxicity versus conventional IMRT without significantly increasing genitourinary toxicity.
CT-guided online adaptation improved prostate SBRT dosimetry
CT-guided online adaptive prostate SBRT was feasible, with adapted plans selected in 95% of fractions and dosimetric improvements in 85%.
MIM software accelerated sarcopenia screening during prostate radiotherapy planning
MIM-based skeletal muscle index measurement matched ImageJ while reducing processing time from 10 to 3.5 minutes.